EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Ginsenoside Rh2 augmented anti-PD-L1 immunotherapy by reinvigorating CD8+ T cells via increasing intratumoral CXCL10

Mu-Yang Huang, Yu-Chi Chen, Wen-Yu Lyu, Xin-Yu He, Zi-Han Ye, Can-Yu Huang, Xin-Ling He, Xiuping Chen, Xiaobing Chen, Baoxian Zhang, Guoyin Kai, Xiaolei Zhang und 3 weitere

Pharmacological Research · 2023

DOI: 10.1016/j.phrs.2023.106988 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacological Research, 2023. Verfasst von Mu-Yang Huang und 14 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao Special Administrativ…. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, B7-H1 Antigen. Die Arbeit wurde bisher 68-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Profiting from the sustained clinical improvement and prolonged patient survival, immune checkpoint blockade of programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) axis has emerged as a revolutionary cancer therapy approach. However, the anti-PD-1/PD-L1 antibodies only achieve a clinical response rate of approximately 20%. Herein, we identified a novel combination strategy that Chinese medicine ginseng-derived ginsenoside Rh2 (Rh2) markedly improved the anti-cancer efficacy of anti-PD-L1 antibody in mice bearing MC38 tumor. Rh2 combined with anti-PD-L1 antibody (combo treatment) further triggered the infiltration, proliferation and activation of CD8+ T cells in the tumor microenvironment (TME). Depletion of CD8+ T cells by mouse CD8 blocking antibody abolished the anti-cancer effect of combo treatment totally. Mechanistically, combo treatment further increased the expression of CXCL10 through activating TBK1-IRF3 signaling pathway, explaining the increased infiltration of T cells. Employing anti- CXC chemokine receptor 3 (CXCR3) blocking antibody prevented the T cells infiltration and abolished the anti-cancer effect of combo treatment. Meanwhile, combo treatment increased the percentage of M1-like macrophages and raised the ratio of M1/M2 macrophages in TME. By comparing the anti-cancer effect of combo treatment among MC38, CT26 and 4T1 tumors, resident T cells were considered as a prerequisite for the effectiveness of combo treatment. These findings demonstrated that Rh2 potentiated the anti-cancer effect of PD-L1 blockade via promoting the T cells infiltration and activation, which shed a new light on the combination strategy to enhance anti-PD-L1 immunotherapy by using natural product Rh2.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD8-Positive T-LymphocytesB7-H1 AntigenHumansAnimalsMiceCell Line, TumorImmunotherapyTumor MicroenvironmentChemokine CXCL10Ginsenosides

Stichwörter der Autor:innen

Combination treatmentGinsenoside Rh2PD-1/PD-L1T cellsTumor microenvironment

Substanzen

B7-H1 AntigenChemokine CXCL10CD274 protein, humanginsenoside Rh2GinsenosidesCXCL10 protein, human

Autor:innen und Institutionen

  • State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao Special Administrative Region of China.
  • State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao Special Administrative Region of China; Department of Pharmaceutical Sciences, Faculty of H…
  • Increasepharm (Hengqin) Innovative Medicine Institute Limited, Zhuhai, China.
  • Zhejiang Provincial International S&T Cooperation Base for Active Ingredients of Medicinal and Edible Plants and Health, School of Pharmaceutical Sciences, The Third Affiliated Hospital, Zhejiang Chinese Medical Univers…
  • National-Local Joint Engineering Laboratory of Druggability and New Drug Evaluation, Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou,…
  • State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao Special Administrative Region of China. Electronic address: tingli@um.edu.mo.

Zitieren

APA

Huang, M. Y., Chen, Y. C., Lyu, W. Y., He, X. Y., Ye, Z. H., Huang, C. Y., He, X. L., Chen, X., Chen, X., Zhang, B., Kai, G., Zhang, X., Li, T., Huang, M., & Lu, J. J. (2023). Ginsenoside Rh2 augmented anti-PD-L1 immunotherapy by reinvigorating CD8+ T cells via increasing intratumoral CXCL10. Pharmacological Research. https://doi.org/10.1016/j.phrs.2023.106988

Vancouver

Huang MY, Chen YC, Lyu WY, He XY, Ye ZH, Huang CY, et al. Ginsenoside Rh2 augmented anti-PD-L1 immunotherapy by reinvigorating CD8+ T cells via increasing intratumoral CXCL10. Pharmacological Research. 2023. doi:10.1016/j.phrs.2023.106988

BibTeX
@article{Huang2023,
  author = {Huang, Mu-Yang and Chen, Yu-Chi and Lyu, Wen-Yu and He, Xin-Yu and Ye, Zi-Han and Huang, Can-Yu and He, Xin-Ling and Chen, Xiuping and Chen, Xiaobing and Zhang, Baoxian and Kai, Guoyin and Zhang, Xiaolei and Li, Ting and Huang, Mingqing and Lu, Jin-Jian},
  title = {Ginsenoside Rh2 augmented anti-PD-L1 immunotherapy by reinvigorating CD8+ T cells via increasing intratumoral CXCL10},
  journal = {Pharmacological Research},
  year = {2023},
  doi = {10.1016/j.phrs.2023.106988}
}
Kostenlos starten →